Global Atypical Hemolytic Uremic Syndrome Treatment Market - 2023-2030

Global Atypical Hemolytic Uremic Syndrome Treatment Market - 2023-2030

Global Atypical Hemolytic Uremic Syndrome Treatment Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period 2023-2030.

Atypical hemolytic uremic syndrome (aHUS) is a potentially life-threatening condition that causes small blood clots and organ damage. It’s often caused by a genetic mutation that affects the immune system. It is a very rare genetic disease that causes tiny blood clots to form in your blood vessels, blocking blood flow to important organs. aHUS can cause kidney failure, heart disease, and other serious health problems.

The atypical hemolytic uremic syndrome can be diagnosed with several tests that include complete blood count (CBC) and kidney function tests, genetic testing, stool tests, kidney biopsy and others.

Market Dynamics: Drivers & Restraints

Increase in the availability of treatments

Market expansion is anticipated to be driven by the growing number of treatment alternatives being introduced and the rising level of patient awareness. The fundamental causes of aHUS, such as complement dysregulation, are the focus of recently developed therapeutics.

For those suffering from aHUS, these therapies provide novel avenues for treatment. Numerous nations are promoting research on uncommon diseases, such as aHUS, through scientific initiatives. Patients, caregivers, and medical professionals are becoming increasingly aware of aHUS as more is known about the condition. Patient outcomes are being improved by the early diagnosis and treatment of aHUS brought about by this greater knowledge.

Restraint

High cost of the treatment

The cost of aHUS treatment can be very high, which can limit access to care for some patients. The high cost is due to the complexity of the disease, the need for specialized treatment, and the relatively low patient population. Thus, the above factors are expected to hinder the market growth.

Segment Analysis

The global atypical hemolytic uremic syndrome treatment market is segmented based on treatment type, end-user, and region.

Venous Stents segment accounted for 56.3% of the market share

Atypical hemolytic uremic syndrome (aHUS) is caused by dysregulation of the complement system, leading to complement overactivation. Drugs segment holds a dominant position over other types of treatments. This is due to their safety and efficiency in the treatment of the disease.

Eculizumab is a newly developed biologic that blocks the terminal complement pathway and has been successfully used in the treatment of aHUS. Eculizumab (Soliris), the only approved treatment for aHUS,15, 16 is a humanized monoclonal antibody that binds with high affinity to the human C5 complement protein and blocks the formation of proinflammatory C5a and lytic C5b.

Ravulizumab is approved for the treatment of atypical hemolytic uraemic syndrome (aHUS) in several countries, including the United States and the European Union. Ravulizumab was re-engineered from eculizumab to have a longer terminal elimination half-life, resulting in a more convenient maintenance dose regimen of once every 4-8 weeks versus once every 2-3 weeks for eculizumab. Thus, the above factors are expected to hold the segment in the dominant position.

Geographical Analysis

North America is expected to hold a significant position in the global atypical hemolytic uremic syndrome treatment market share

North America is expected to hold a dominant position in the market share. In comparison to other locations, North America has a comparatively high frequency of aHUS, which raises the need for aHUS treatment. New treatments and cures for aHUS have been developed as a result of North America's long history of innovation and technology developments in the healthcare industry. The area also boasts a thriving healthcare sector with cutting-edge medical facilities and highly qualified medical personnel, all of which improve the standard of care for patients with aHUS.

Governments in North America are taking steps to promote research into rare diseases, including aHUS, and this support is driving the development of new therapies and improving access to existing treatments. There is growing awareness of aHUS among patients, caregivers, and healthcare professionals in North America, leading to earlier diagnosis and treatment of the disease.

COVID-19 Impact Analysis

COVID-19 has had a significant impact on the growth of the market. The delayed approvals and launches have caused the lack of availability of drugs to the patients. The companies have shifted their focus towards the manufacturing of COVID-19 medicine. The supply chains have been interrupted due to the implementation of the lockdown.

Market Segmentation

By Treatment Type
• Drug Type
Eculizumab
Ravulizumab
• Procedure
Plasma Therapy
Dialysis
Kidney Transplant

By End-User
• Hospital
• Specialty Clinics
• Ambulatory Surgical Centers

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The leading companies with a significant market share include Alexion Pharmaceuticals, Inc., Novartis AG, AstraZeneca Plc, GNHIndia, Omeros Corporation, Chugai Pharmaceutical Co., Ltd., and Bio-Rad Laboratories, Inc. and among others. among others

Why Purchase the Report?
• To visualize the global atypical hemolytic uremic syndrome treatment market segmentation based on treatment type, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of atypical hemolytic uremic syndrome treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global atypical hemolytic uremic syndrome treatment market report would provide approximately 47 tables, 48 figures, and 176 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies